FUSN NASDAQ
Fusion Pharmaceuticals Inc.
1W: +0.5%
1M: +0.5%
3M: +105.2%
1Y: +339.8%
3Y: +164.4%
$21.55
Last traded 2024-06-04 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$2M
+41.5% ▲
Gross Profit
$723K
+101.3% ▲
Operating Income
-$99M
-12.7% ▼
Net Income
-$95M
-8.3% ▼
EPS (Diluted)
$-1.45
+27.5% ▲
EBITDA
-$88M
-11.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1M | $1M | $2M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +1.5% | +41.5% |
| Cost of Revenue | $290K | $482K | $56M | $59M | $1M |
| Gross Profit | -$290K | -$482K | -$55M | -$57M | $723K |
| Gross Margin | — | — | -3813.7% | -3931.1% | 35.0% |
| R&D Expenses | $11M | $17M | $56M | $59M | $69M |
| SG&A Expenses | $8M | $21M | $27M | $31M | $31M |
| Operating Expenses | $18M | $38M | $83M | $89M | $100M |
| Operating Income | -$18M | -$38M | -$82M | -$88M | -$99M |
| Operating Margin | — | — | -5695.5% | -6025.6% | -4798.5% |
| Interest Expense | $0 | $327K | $0 | $2M | $5M |
| Income Before Tax | -$16M | -$76M | -$81M | -$89M | -$94M |
| Tax Expense | $251K | $3M | -$118K | -$2M | $787K |
| Net Income | -$16M | -$78M | -$81M | -$88M | -$95M |
| Net Margin | — | — | -5628.3% | -5996.7% | -4588.8% |
| EPS (Diluted) | $-0.10 | $-3.56 | $-1.90 | $-2.00 | $-1.45 |
| EBITDA | -$18M | -$31M | -$81M | -$87M | -$88M |
| Shares Outstanding | 156M | 22M | 43M | 44M | 66M |